SeaSpine Announces Limited Commercial Launch of WaveForm C 3D-Printed Interbody Implant System - Seite 2
*Data on file
About SeaSpine
SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal
disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need
to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are
designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal implants portfolio consists of an extensive
line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Expertise in both orthobiologic sciences and spinal implants
product development allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in
the United States and in approximately 30 countries worldwide through a committed network of increasingly exclusive distribution partners.
Lesen Sie auch
Forward-Looking Statements
SeaSpine cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that are based on the Company’s current
expectations and assumptions. Such forward-looking statements include, but are not limited to, statements relating to: the number of 3D-printed interbody devices that the Company anticipates
launching by mid-2021; and the objectives of product design and the ability of the underlying products to achieve design objectives, including maximizing patient outcomes, providing efficiency for
the surgeon and fusion for the patient, balancing key geometric, manufacturing and clinical requirements, and working with the Company’s allograft demineralized bone matrix offerings. Among the
factors that could cause or contribute to material differences between the Company’s actual results and the expectations indicated by the forward-looking statements are risks and uncertainties that
include, but are not limited to: the ability of newly launched products to perform as designed and intended and to meet the needs of surgeons and patients, including as a result of the lack of
clinical validation of products in limited commercial (or “alpha”) launch; unexpected delay, including as a result of developing and supporting the launch of new products, including as a result of
obtaining regulatory clearances; and other risks and uncertainties more fully described in the Company’s news releases and periodic filings with the Securities and Exchange Commission. The
Company’s public filings with the Securities and Exchange Commission are available at www.sec.gov.